Matthias Gehringer
Overview
Explore the profile of Matthias Gehringer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang G, Seidler N, Rohm S, Pan Y, Liang X, Haarer L, et al.
Angew Chem Int Ed Engl
. 2024 Dec;
64(8):e202419736.
PMID: 39716901
Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases. A major challenge in designing inhibitors for...
2.
Schiedel M, Barbie P, Pape F, Pinto M, Unzue Lopez A, Mendez M, et al.
ChemMedChem
. 2024 Sep;
19(23):e202400543.
PMID: 39308157
The Frontiers in Medicinal Chemistry (FiMC) is the largest international Medicinal Chemistry conference in Germany and took place from March 17 to 20 2024 in Munich. Co-organized by the Division...
3.
Heppner D, Ogboo B, Urul D, May E, Schaefer E, Murkin A, et al.
J Med Chem
. 2024 Aug;
67(17):14693-14696.
PMID: 39115869
No abstract available.
4.
Klett T, Schwer M, Ernst L, Engelhardt M, Jaag S, Masberg B, et al.
Drug Des Devel Ther
. 2024 Jul;
18:2653-2679.
PMID: 38974119
Purpose: Over the last few years, covalent fragment-based drug discovery has gained significant importance. Thus, striving for more warhead diversity, we conceived a library consisting of 20 covalently reacting compounds....
5.
Hillebrand L, Liang X, Serafim R, Gehringer M
J Med Chem
. 2024 May;
67(10):7668-7758.
PMID: 38711345
Covalent inhibitors and other types of covalent modalities have seen a revival in the past two decades, with a variety of new targeted covalent drugs having been approved in recent...
6.
Schwarz M, Kurkunov M, Wittlinger F, Rudalska R, Wang G, Schwalm M, et al.
J Med Chem
. 2024 Apr;
67(8):6549-6569.
PMID: 38604131
Fibroblast growth factor receptor 4 (FGFR4) is thought to be a driver in several cancer types, most notably in hepatocellular carcinoma. One way to achieve high potency and isoform selectivity...
7.
Albertini C, Petralla S, Massenzio F, Monti B, Rizzardi N, Bergamini C, et al.
Arch Pharm (Weinheim)
. 2024 Feb;
357(6):e2300525.
PMID: 38412454
Lewy body dementia (LBD) represents the second most common neurodegenerative dementia but is a quite underexplored therapeutic area. Nepflamapimod (1) is a brain-penetrant selective inhibitor of the alpha isoform of...
8.
Serafim R, Gehringer M, Borsari C
Pharmaceuticals (Basel)
. 2024 Feb;
17(2).
PMID: 38399421
Covalent inhibitors have experienced a revival in medicinal chemistry and chemical biology in recent decades [...].
9.
Laufer S, Gehringer M, Titz A
J Med Chem
. 2024 Feb;
67(4):2237.
PMID: 38305161
No abstract available.
10.
Hillebrand L, Gehringer M
Chimia (Aarau)
. 2023 Dec;
76(5):435-447.
PMID: 38069715
Covalent inhibitors have recently seen a revival in medicinal chemistry. Inhibitors addressing non-catalytic cysteine residues with weakly reactive electrophiles have been very successfully employed to target protein kinases, one of...